Junmin Song
Clinical FellowAbout
Research
Publications
Featured Publications
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.
Park W, O'Connor CA, Chou JF, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Homsi R, Sivaprakasam K, Umeda S, Perry MA, Varghese AM, Yu KH, Balogun F, Zervoudakis A, Katz SS, Kim TH, Zhao K, Richards AL, Lecomte N, Martin Muldoon D, Karnoub E, Chatila W, Yang J, El-Dika I, Rao D, Joshi S, Foote MB, Sugarman R, Harding JJ, Epstein AS, Kelsen D, Chalassani S, Keane F, Schoenfeld JD, Singhal A, Diguglielmo E, Bandlamudi C, Song J, Ozkan HS, Hong J, Zhang H, Cardenas AI, Lao M, Melchor J, Shah R, Kang W, Mazzoni F, Soares K, Donoghue MT, Santos E, Rolston V, Reyngold M, Wei AC, Tipping M, Basturk O, Berger M, Kihn Do R, Schattner M, Jarnagin WR, Riaz N, Balachandran V, Pe'er D, Capanu M, Iacobuzio-Donahue C, O'Reilly EM. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Nat Med 2026, 32: 1783-1793. PMID: 41882405, DOI: 10.1038/s41591-026-04299-5.Peer-Reviewed Original ResearchThoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches
Song J, Gersten A, Herzberg B, Halmos B. Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches. The Oncologist 2025, 30: oyaf121. PMID: 40421964, PMCID: PMC12107547, DOI: 10.1093/oncolo/oyaf121.Peer-Reviewed Original ResearchTreatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC.
Lee M, Song J, Miao E, Alicea DS, Zhang C, Xue X, Tuckman S, Yang J, D'Aiello A, Gucalp R, Stiles B, Ohri N, Halmos B, Cheng H. Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC. NPJ Precis Oncol 2026, 10 PMID: 41593317, DOI: 10.1038/s41698-025-01259-z.Peer-Reviewed Original ResearchTeclistamab versus B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis
Song J, Chiang C, Esagian S, Kim G, Chi K, Chang Y, Parker T, Mehta A. Teclistamab versus B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis. Haematologica 2025, 110: 2498-2502. PMID: 40207713, PMCID: PMC12485301, DOI: 10.3324/haematol.2024.287215.Peer-Reviewed Original ResearchGlucagon-like Peptide‐1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors
Chiang C, Song J, Chi K, Chang Y, Xanthavanij N, Chang Y, Hsia Y, Chiang C, Ghamari A, Reynolds K, Lin S, Xu X, Neilan T. Glucagon-like Peptide‐1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors. European Journal Of Cancer 2024, 216: 115170. PMID: 39709670, DOI: 10.1016/j.ejca.2024.115170.Peer-Reviewed Original ResearchGLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance
Chi K, Song J, Desphande S, Lee P, Soni A, Gonzales-Uribe A, Lessa Y, Morgan A, Chang Y, Lin Y, Akman Z, Nouri A, Rossi R, Babapour G, Varrias D, Parker T, Baldassarre L, Jha A, Muchtar E, Hull S, Kwan J, Nanna M. GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance. JAMA Network Open 2025, 8: e2517541. PMID: 40587132, PMCID: PMC12210086, DOI: 10.1001/jamanetworkopen.2025.17541.Peer-Reviewed Original ResearchGlucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation
Chiang C, Song J, Chang Y, Osataphan S, Lee Y, Chang K, Chi K, Chiang C, Dua A, Lake L, Lauw M, Bauer K, Kazi D, Patell R. Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation. Blood Advances 2025, 9: 2410-2418. PMID: 39908569, PMCID: PMC12142527, DOI: 10.1182/bloodadvances.2025015871.Peer-Reviewed Original ResearchUpdate 2025: Management of Non‑Small-Cell Lung Cancer.
Jeon H, Wang S, Song J, Gill H, Cheng H. Update 2025: Management of Non‑Small-Cell Lung Cancer. Lung 2025, 203: 53. PMID: 40133478, DOI: 10.1007/s00408-025-00801-x.Peer-Reviewed Original Research
2026
Glucagon-like peptide receptor agonists (GLP-1RAs) as cardiovascular risk modifiers in obstructive sleep apnea and obesity: a real-world study
Ahn J, Song J, Admire K, Chang Y, Chi K, Gordon N, Sill J. Glucagon-like peptide receptor agonists (GLP-1RAs) as cardiovascular risk modifiers in obstructive sleep apnea and obesity: a real-world study. Journal Of Clinical Sleep Medicine 2026, 22: 102. PMID: 42387223, PMCID: PMC13323676, DOI: 10.1007/s44470-026-00110-x.Peer-Reviewed Original ResearchRacial and socioeconomic disparities in patients with Waldenström Macroglobulinemia: a SEER database analysis.
Alvarez Soto A, Song J, Braun M, Kumar S. Racial and socioeconomic disparities in patients with Waldenström Macroglobulinemia: a SEER database analysis. Sci Rep 2026, 16 PMID: 42236801, DOI: 10.1038/s41598-026-54387-2.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Get In Touch
Contacts
Email